BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 23364483)

  • 1. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
    Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
    Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
    Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
    Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Mar; 49(3):141-75. PubMed ID: 20170205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients.
    Cho JH; Yoon YD; Park JY; Song EJ; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):109-14. PubMed ID: 22310591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients.
    Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E
    Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms.
    Op den Buijsch RA; Christiaans MH; Stolk LM; de Vries JE; Cheung CY; Undre NA; van Hooff JP; van Dieijen-Visser MP; Bekers O
    Fundam Clin Pharmacol; 2007 Aug; 21(4):427-35. PubMed ID: 17635182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
    Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
    Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation.
    Bouamar R; Hesselink DA; van Schaik RH; Weimar W; Macphee IA; de Fijter JW; van Gelder T
    Ther Drug Monit; 2011 Apr; 33(2):178-84. PubMed ID: 21383650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
    Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
    Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
    Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
    J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
    Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
    Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of ABCB1 diplotype on tacrolimus disposition in renal recipients depends on CYP3A5 and CYP3A4 genotype.
    Vanhove T; Annaert P; Lambrechts D; Kuypers DRJ
    Pharmacogenomics J; 2017 Dec; 17(6):556-562. PubMed ID: 27378609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABCB1 haplotype influences the sirolimus dose requirements in Chinese renal transplant recipients.
    Lee J; Huang H; Chen Y; Lu X
    Biopharm Drug Dispos; 2014 Apr; 35(3):164-72. PubMed ID: 24285256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients.
    Provenzani A; Notarbartolo M; Labbozzetta M; Poma P; Vizzini G; Salis P; Caccamo C; Bertani T; Palazzo U; Polidori P; Gridelli B; D'Alessandro N
    Int J Mol Med; 2011 Dec; 28(6):1093-102. PubMed ID: 21922127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients.
    Elens L; Bouamar R; Hesselink DA; Haufroid V; van der Heiden IP; van Gelder T; van Schaik RH
    Clin Chem; 2011 Nov; 57(11):1574-83. PubMed ID: 21903774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.
    Rahsaz M; Azarpira N; Nikeghbalian S; Aghdaie MH; Geramizadeh B; Moini M; Banihashemi M; Darai M; Malekpour Z; Malekhosseini SA
    Exp Clin Transplant; 2012 Feb; 10(1):24-9. PubMed ID: 22309416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.